Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune ...
Edesa Biotech, Inc. announced a successful private placement led by Velan Capital, raising approximately $15 million to advance its CXCL10 antibody program through fiscal 2026. The offering included ...
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results